Icon Plc (ICLR) Receives Consensus Rating of “Hold” from Brokerages
Icon Plc (NASDAQ:ICLR) has received an average rating of “Hold” from the ten research firms that are presently covering the company. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $82.29.
Several equities analysts recently commented on ICLR shares. Mizuho started coverage on shares of Icon Plc in a report on Thursday, March 23rd. They set a “neutral” rating and a $66.00 price target on the stock. Zacks Investment Research downgraded shares of Icon Plc from a “hold” rating to a “sell” rating in a report on Wednesday, April 26th. Evercore ISI upped their price target on shares of Icon Plc from $91.50 to $92.00 and gave the company an “outperform” rating in a report on Friday, April 28th. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of Icon Plc in a report on Thursday, May 11th.
Institutional investors have recently modified their holdings of the company. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Icon Plc by 27.2% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,460 shares of the medical research company’s stock worth $111,000 after buying an additional 312 shares in the last quarter. Flinton Capital Management LLC bought a new position in shares of Icon Plc during the fourth quarter worth approximately $125,000. US Bancorp DE increased its position in shares of Icon Plc by 15.0% in the first quarter. US Bancorp DE now owns 1,929 shares of the medical research company’s stock worth $154,000 after buying an additional 251 shares in the last quarter. Quantbot Technologies LP increased its position in shares of Icon Plc by 40.9% in the first quarter. Quantbot Technologies LP now owns 2,022 shares of the medical research company’s stock worth $161,000 after buying an additional 587 shares in the last quarter. Finally, IFP Advisors Inc increased its position in shares of Icon Plc by 2.7% in the first quarter. IFP Advisors Inc now owns 2,232 shares of the medical research company’s stock worth $178,000 after buying an additional 59 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Icon Plc (ICLR) Receives Consensus Rating of “Hold” from Brokerages” was published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/26/icon-plc-iclr-receives-consensus-rating-of-hold-from-brokerages.html.
Icon Plc (NASDAQ:ICLR) traded up 1.96% during mid-day trading on Friday, hitting $91.73. 182,582 shares of the stock were exchanged. The company’s 50-day moving average price is $84.22 and its 200 day moving average price is $81.05. Icon Plc has a 52 week low of $63.91 and a 52 week high of $91.94. The firm has a market capitalization of $4.93 billion, a price-to-earnings ratio of 19.04 and a beta of 0.63.
Icon Plc (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, April 27th. The medical research company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.27 by $0.02. The company had revenue of $432 million for the quarter, compared to the consensus estimate of $432.21 million. Icon Plc had a net margin of 15.60% and a return on equity of 29.47%. The firm’s revenue was up 7.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.12 EPS. Equities research analysts expect that Icon Plc will post $5.17 EPS for the current year.
About Icon Plc
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.